权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Repertoire studies of human antibodies to RSV and MPV F

RSV 和 MPV F 人类抗体的谱研究

基本信息

批准号：
10249184
负责人：
Theodore S Jardetzky
金额：
$ 62.19万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-06 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10249184
关键词：
Address Animals Antibodies Antibody Response Antibody-mediated protection Antigenic Variation Antigens Antiviral Agents B cell repertoire B-Lymphocytes Biochemical Bronchiolitis Child Chimeric Proteins Clinic Visits Collaborations Disease Outbreaks Elderly Engineering Epidemiology Epitope Mapping Epitopes Family Frequencies Health Hospitalization Human Human Metapneumovirus Immune response Immune system Immunity Immunoglobulin A Immunologics Individual Infant Infection Knowledge Laboratories Life Maps Medical Modification Molecular Conformation Morbidity - disease rate Mutate Mutation Palivizumab Para-Influenza Virus Type 3 Paramyxovirus Pneumonia Pneumovirus Population Prophylactic treatment Protein Conformation Research Personnel Respiratory Syncytial Virus Infections Respiratory syncytial virus Sampling Specificity Structure Subunit Vaccines Universities Vaccine Design Vaccines Variant Viral Virus Visit base comparative cross reactivity high risk human pathogen influenzavirus insight member murine monoclonal antibody neutralizing antibody novel novel strategies protein folding recurrent infection respiratory respiratory virus response small molecule tool vaccine development viral entry inhibitor

项目摘要

Project Summary In this project, the Jardetzky and Crowe laboratories will collaborate to investigate the neutralizing antibody response to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), using complementary structural, biochemical and immunological approaches. RSV and HMPV are respiratory viruses that cause widespread morbidity within the human population second only to influenza virus. RSV is the most common cause of bronchiolitis and pneumonia in infants worldwide. The virus also impacts the elderly and others with weakened immune systems. HMPV was identified in 2001 and has been causing respiratory illnesses in the human population for over 50 years. Similar to RSV, HMPV infections are associated with a significant burden of hospitalizations and clinic visits in young children and in the elderly. Despite limited antigenic variation, RSV and HMPV cause repeated infections throughout life and are associated with a lack of induction of durable immunity. A clear explanation for this ability of the viruses to reinfect previously exposed individuals is still lacking, although multiple hypotheses have been developed. The RSV and HMPV fusion (F) proteins are the major targets of neutralizing antibodies (nAbs), and nAbs targeting the prefusion conformation of the RSV F protein have been shown to be the most potent inhibitors of viral entry. However, our understanding of the antibody response to HMPV is much more limited. In this proposal, the Jardetzky and Crowe laboratories will address outstanding issues in RSV and HMPV antibody immunity by studying monoclonal and repertoire- based B cell responses to both viruses, conducting functional and structural mapping of antibody epitopes and studying the sequence determinants of HMPV F conformational stabilization. !

项目总结